Galmed Pharmaceuticals EOCN
NASDAQ EOCN
$3.01 -0.06 (-1.95%)
As of: Oct 21, 2026 · 2:30 PM EDT

Galmed Pharmaceuticals (EOCN) Current Deferred Revenue (2016 - 2018)

Updated

Galmed Pharmaceuticals' Current Deferred Revenue came in at $270,000 for Q1 2018, down 75.1% from $1.09 million a year earlier and down 49.8% from the prior quarter.

Analysis

Galmed Pharmaceuticals (EOCN) Current Deferred Revenue (2016 - 2018) Analysis & Trends

At the end of FY2017, Galmed Pharmaceuticals' Current Deferred Revenue was $538,000, down 50.8% from FY2016.

  • Going back by year, Current Deferred Revenue was $1.09 million in FY2016.
  • Year-over-year, Current Deferred Revenue has declined for three consecutive quarters.
  • Business Quant data shows EOCN's Current Deferred Revenue at $538,000 (Q4 2017), $811,000 (Q3 2017) and $1.09 million (Q2 2017) in the three quarters before Q1 2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.76 Bn 1,105.35 Bn 19.71 Bn
2 Johnson & Johnson 618.64 Bn 537.17 Bn 17.26 Bn
3 AbbVie 502.02 Bn 475.13 Bn 12.70 Bn
4 Merck 368.10 Bn 322.48 Bn 12.21 Bn
5 Novartis Ag 297.96 Bn 261.95 Bn 11.24 Bn
6 Astrazeneca 261.11 Bn 234.80 Bn 12.86 Bn
7 Amgen 236.64 Bn 192.04 Bn 7.24 Bn
8 Gilead Sciences 191.15 Bn 165.35 Bn 6.22 Bn
9 Pfizer 169.69 Bn 116.33 Bn 10.94 Bn
10 Galmed Pharmaceuticals 1.62 Mn -39.07 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2018 270,000.00
Dec 31, 2017 538,000.00
Sep 30, 2017 811,000.00
Jun 30, 2017 1.09 Mn
Mar 31, 2017 1.09 Mn
Dec 31, 2016 1.09 Mn
Sep 30, 2016 1.05 Mn
API Access

Galmed Pharmaceuticals Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=EOCN&period=max&api_key=YOUR_API_KEY